Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2019

Lumoxiti Now Covered with Prior Authorization

In September, the Food and Drug Administration approved the drug Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. Effective immediately, Harvard Pilgrim will provide coverage for commercial members for Lumoxiti (moxetumomab pasudotox-tdfk) with prior authorization from CVS Health—NovoLogix, when all of the following criteria are met:

  • The patient has received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
  • The patient has not previously received 6 or more cycles of treatment with Lumoxiti.

Please use the unlisted code J3590 (unclassified biologics) when billing for the use of Lumoxiti. (For information on billing unlisted codes, please refer to the Injectable and Implantable Drugs Payment Policy.) To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For complete information, please refer to Harvard Pilgrim’s new Lumoxiti Prior Authorization Policy and the associated prior authorization request form, which you can you can find on the Medical Drug Prior Authorization page in the Provider section of Harvard Pilgrim’s website.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


HPHConnect for Providers Getting a New Look in 2019

2019 Quality Grant Applications Due by Feb. 15

HEDIS 2019 Coming Soon: Your Cooperation is Crucial

HPI to Administer BMC HealthNet Plan

Behavioral Health: Services for Improved Access


New Opioid Safety Edits for 2019 Medicare Advantage Plans

Medical Policy Update: Tumor Treating Fields

Reminder: Formulas and Enteral Nutrition Require Prior Authorization

Updates to Proton Beam Therapy Medical Policy

Lumoxiti Now Covered with Prior Authorization

TriVisc and Jivi Now Covered with Prior Authorization

Pharmacy and Therapeutics Committee Meeting Update


Coding Program Launching in January for Medicare Advantage


Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator